Skip to main content

As the situation in Ukraine evolves, businesses should be mindful of potential risks to their people, assets, operations, or supply chains in the region and globally. Marsh, as part of the Marsh McLennan family of companies, has created a page with information, tools, and resources related to the Russia-Ukraine conflict. Please visit the page for the latest information.

Gene therapy and your employee benefits plan

As the gene therapy pipeline grows, so do the likely claims and potential financial risk for plan sponsors. We want to help you understand those risks as well as the options available to you to help mitigate or minimize them.

Before a claim occurs, do you know what your plan covers?

Modern medicine frequently accomplishes incredible things. From finding new ways to treat “old” conditions to addressing emerging challenges head-on, the field is constantly being pushed forward in new, exciting ways. Undoubtedly, one of the best examples of this is the advent of gene therapy. Gene therapy today is comprised of a variety of methods and treatments, though the basic principle is the same. While gene therapy can be life-altering for those who receive it, it can be equally as momentous for employers and plan sponsors faced with a colossal claim they may not be prepared for. A gene therapy claim can be both extremely costly and entirely unexpected—a combination that could be disastrous.


How can you be better prepared for a gene therapy claim?

Download the report to find out more.

Interested in learning more? Download the report.